GLP-1 derivative and preparation thereof absorbable via mucous membrane


Ontology type: sgo:Patent     


Patent Info

DATE

2007-11-06T00:00

AUTHORS

Yuji Hayashi , Mitsuhiro Makino , Toshiyuki Kouzaki , Motohiro Takeda , Takahito Jomori

ABSTRACT

A GLP-1 derivative is provided including an amino acid sequence of GLP-1 (7-35) having deletion, substitution and/or addition of one or more amino acids and having Waa-(Xaa)n-Yaa (in which Waa is Arg or Lys, Xaa is Arg or Lys, n is an integer of 0 to 14, and Yaa is Arg, Arg-NH2, Lys, Lys-NH2 or Hse) added to the C-terminus of the peptide having a GLP-1 activity. These derivatives are highly absorbable via a mucous membrane. The GLP-1 derivative can be conferred with resistance to dipeptidyl peptidase IV by substituting amino acid 8 in its GLP-1 amino acid sequence with Ser, or with resistance to trypsin by substituting amino acids 26 and 34 with Gln and Asn, respectively.The absorption efficiency of the GLP-1 derivatives via mucous membranes can be further improved by preparing a composition using a charge-regulated fat emulsion regulated to be negatively charged thereon. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2581", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "Yuji Hayashi", 
        "type": "Person"
      }, 
      {
        "name": "Mitsuhiro Makino", 
        "type": "Person"
      }, 
      {
        "name": "Toshiyuki Kouzaki", 
        "type": "Person"
      }, 
      {
        "name": "Motohiro Takeda", 
        "type": "Person"
      }, 
      {
        "name": "Takahito Jomori", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s001250050903", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013633156", 
          "https://doi.org/10.1007/s001250050903"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001250050903", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013633156", 
          "https://doi.org/10.1007/s001250050903"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/bi0014498", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055162497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/bi0014498", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055162497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.20.12.1874", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070747521"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-11-06T00:00", 
    "description": "

A GLP-1 derivative is provided including an amino acid sequence of GLP-1 (7-35) having deletion, substitution and/or addition of one or more amino acids and having Waa-(Xaa)n-Yaa (in which Waa is Arg or Lys, Xaa is Arg or Lys, n is an integer of 0 to 14, and Yaa is Arg, Arg-NH2, Lys, Lys-NH2 or Hse) added to the C-terminus of the peptide having a GLP-1 activity. These derivatives are highly absorbable via a mucous membrane. The GLP-1 derivative can be conferred with resistance to dipeptidyl peptidase IV by substituting amino acid 8 in its GLP-1 amino acid sequence with Ser, or with resistance to trypsin by substituting amino acids 26 and 34 with Gln and Asn, respectively.

The absorption efficiency of the GLP-1 derivatives via mucous membranes can be further improved by preparing a composition using a charge-regulated fat emulsion regulated to be negatively charged thereon.

", "id": "sg:patent.US-7291594-B2", "keywords": [ "derivative", "preparation", "Mucous Membrane", "amino acid sequence", "Glucagon-Like Peptide 1", "deletion", "substitution", "amino acid", "Arg", "integer", "Lys", "NHS", "HSE", "C-terminus", "peptide", "GLP", "resistance", "peptidase", "Ser", "trypsin", "Gln", "absorption", "composition", "emulsion" ], "name": "GLP-1 derivative and preparation thereof absorbable via mucous membrane", "recipient": [ { "id": "https://www.grid.ac/institutes/grid.453364.3", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-7291594-B2" ], "sdDataset": "patents", "sdDatePublished": "2019-04-18T10:29", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-uberresearch-data-patents-target-20190320-rc/data/sn-export/402f166718b70575fb5d4ffe01f064d1/0000100128-0000352499/json_export_03196.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-7291594-B2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-7291594-B2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-7291594-B2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-7291594-B2'


 

This table displays all metadata directly associated to this object as RDF triples.

72 TRIPLES      15 PREDICATES      41 URIs      32 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-7291594-B2 schema:about anzsrc-for:2581
2 schema:author Ndde9ed20051b430dabe349793b090d93
3 schema:citation sg:pub.10.1007/s001250050903
4 https://doi.org/10.1021/bi0014498
5 https://doi.org/10.2337/diacare.20.12.1874
6 schema:datePublished 2007-11-06T00:00
7 schema:description <p num="p-0001">A GLP-1 derivative is provided including an amino acid sequence of GLP-1 (7-35) having deletion, substitution and/or addition of one or more amino acids and having Waa-(Xaa)n-Yaa (in which Waa is Arg or Lys, Xaa is Arg or Lys, n is an integer of 0 to 14, and Yaa is Arg, Arg-NH<sub>2</sub>, Lys, Lys-NH<sub>2 </sub>or Hse) added to the C-terminus of the peptide having a GLP-1 activity. These derivatives are highly absorbable via a mucous membrane. The GLP-1 derivative can be conferred with resistance to dipeptidyl peptidase IV by substituting amino acid 8 in its GLP-1 amino acid sequence with Ser, or with resistance to trypsin by substituting amino acids 26 and 34 with Gln and Asn, respectively.</p><p num="p-0002">The absorption efficiency of the GLP-1 derivatives via mucous membranes can be further improved by preparing a composition using a charge-regulated fat emulsion regulated to be negatively charged thereon.</p>
8 schema:keywords Arg
9 C-terminus
10 GLP
11 Gln
12 Glucagon-Like Peptide 1
13 HSE
14 Lys
15 Mucous Membrane
16 NHS
17 Ser
18 absorption
19 amino acid
20 amino acid sequence
21 composition
22 deletion
23 derivative
24 emulsion
25 integer
26 peptidase
27 peptide
28 preparation
29 resistance
30 substitution
31 trypsin
32 schema:name GLP-1 derivative and preparation thereof absorbable via mucous membrane
33 schema:recipient https://www.grid.ac/institutes/grid.453364.3
34 schema:sameAs https://app.dimensions.ai/details/patent/US-7291594-B2
35 schema:sdDatePublished 2019-04-18T10:29
36 schema:sdLicense https://scigraph.springernature.com/explorer/license/
37 schema:sdPublisher N36be438b4130418ebb7b98e60a277a96
38 sgo:license sg:explorer/license/
39 sgo:sdDataset patents
40 rdf:type sgo:Patent
41 N36be438b4130418ebb7b98e60a277a96 schema:name Springer Nature - SN SciGraph project
42 rdf:type schema:Organization
43 N48046b3aa800440fa98de44cd51d459d schema:name Yuji Hayashi
44 rdf:type schema:Person
45 N64a2e85ead394e85967ff99b5a172dfa schema:name Mitsuhiro Makino
46 rdf:type schema:Person
47 Ncb9fed2fa89a445b9a9a9edffc394c4c rdf:first N64a2e85ead394e85967ff99b5a172dfa
48 rdf:rest Nf555a8efa94a49e0911f896e4ac86a86
49 Ndb66f13d2e044a94b4ab6fab4c89a207 rdf:first Neda8126e301242b8aee8e9e06da4cc3b
50 rdf:rest rdf:nil
51 Ndde9ed20051b430dabe349793b090d93 rdf:first N48046b3aa800440fa98de44cd51d459d
52 rdf:rest Ncb9fed2fa89a445b9a9a9edffc394c4c
53 Ne0f979d1fb9241a8bf4b246c936a87aa rdf:first Nf6c86482dd9b4017a07769442a53e5d5
54 rdf:rest Ndb66f13d2e044a94b4ab6fab4c89a207
55 Neda8126e301242b8aee8e9e06da4cc3b schema:name Takahito Jomori
56 rdf:type schema:Person
57 Nf2e6f486a7fb49eab7d90653b865ac25 schema:name Toshiyuki Kouzaki
58 rdf:type schema:Person
59 Nf555a8efa94a49e0911f896e4ac86a86 rdf:first Nf2e6f486a7fb49eab7d90653b865ac25
60 rdf:rest Ne0f979d1fb9241a8bf4b246c936a87aa
61 Nf6c86482dd9b4017a07769442a53e5d5 schema:name Motohiro Takeda
62 rdf:type schema:Person
63 anzsrc-for:2581 schema:inDefinedTermSet anzsrc-for:
64 rdf:type schema:DefinedTerm
65 sg:pub.10.1007/s001250050903 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013633156
66 https://doi.org/10.1007/s001250050903
67 rdf:type schema:CreativeWork
68 https://doi.org/10.1021/bi0014498 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055162497
69 rdf:type schema:CreativeWork
70 https://doi.org/10.2337/diacare.20.12.1874 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070747521
71 rdf:type schema:CreativeWork
72 https://www.grid.ac/institutes/grid.453364.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...